Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323369 | 0.79 | HPGD (0.49) | LMNASMN1; SMN2ALDH1A1ADAMTS4MEN1 | |
| SCHEMBL5323373 | 0.79 | HPGD (0.49) | LMNASMN1; SMN2ALDH1A1ADAMTS4MEN1 | |
| SCHEMBL3078752 | 0.79 | RAB9A (0.52) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL7200135 | 0.79 | RAB9A (0.52) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5062929 | 0.79 | RAB9A (0.52) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5022885 | 0.78 | CXCL8 (0.50) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9706349 | 0.78 | HDAC1 (0.49) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL714235 | 0.78 | SMN1; SMN2 (0.66) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1983877 | 0.78 | HDAC1 (0.49) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3381057 | 0.78 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-15 | — | — | US | claimed |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| CN-105026574-B | Cell lines | 米迪缪尼有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-103917538-B | 2-(1,2,3-triazole-2-base) Benzoylamide and 3-(1,2,3-triazole-2-base) picolinamide derivatives | 埃科特莱茵药品有限公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-2776430-B1 | 2- (1,2,3-TRIAZOL-2-YL) BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL) PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-9150566-B2 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2776430-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068935-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |
| CN-1838950-A | Methods for treating protein aggregation disorders | NEUROCHEM INTERNAT LTD (CH) | 2006-09-27 | — | — | CN | disclosed |
| CN-1575816-A | Compounds for the treatment of female sexual dysfunction | PFIZER (US) | 2005-02-09 | — | — | CN | disclosed |
| CN-1328824-A | Compounds for the treatment of female sexual dysfunction | PFIZER (US) | 2002-01-02 | — | — | CN | disclosed |
| EP-0961779-A1 | SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998032766-A1 | SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| EP-0146363-A2 | Synergistic pharmaceutical compositions, their production and use | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | LMNA 2823/4885SMN1; SMN2 3784/4885ALDH1A1 1156/4885 |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | IAPP, NPPA, ARG1 | LMNA 1459/4885SMN1; SMN2 3727/4885ALDH1A1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.